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http://dx.doi.org/10.1016/j.jacl.2015.1BACKGROUND: ETC-1002 is an oral, once-daily, first-in-class medication being developed to treat
hypercholesterolemia.
OBJECTIVES: To compare 2 doses of ETC-1002, alone or combined with ezetimibe 10 mg (EZE),
vs EZE monotherapy for lowering low-density lipoprotein cholesterol (LDL-C).
METHODS: This phase 2b, multicenter, double-blind trial-evaluated hypercholesterolemic patients
(LDL-C, 130 to 220 mg/dL) with (n 5 177) or without (n 5 171) muscle-related intolerance to $2 sta-
tins; 1 at lowest approved dose. Subjects were randomized to 12-week treatment with ETC-1002 120 mg
or ETC-1002 180 mg alone, EZE alone, ETC-1002 120 mg plus EZE, or ETC-1002 180 mg plus EZE.
RESULTS: EZE alone lowered LDL-C by 21%, whereas ETC-1002 monotherapy with 120 mg or
180 mg reduced LDL-C by 27% (P 5 .0008 vs EZE) and 30% (P , .0001 vs EZE), respectively. The
combination of ETC-1002, 120 mg or 180 mg plus EZE reduced LDL-C by 43% and 48%,
respectively (bothP, .0001 vs EZE). ETC-1002 alone or combinedwith EZE also reduced non–high-den-
sity lipoprotein cholesterol, total cholesterol, apolipoprotein B, LDL particle number, and high-sensitivity
C-reactive protein compared with EZE alone. Across all treatment groups, statin-intolerant patients re-
ported more muscle-related adverse events than did statin-tolerant patients. ETC-1002 was safe and
well tolerated, and rates of muscle-related adverse events were similar in all treatment groups.
CONCLUSIONS: In patients with and without statin intolerance, daily treatment with ETC-1002 120mg
and 180 mg alone or with EZE reduced LDL-C more than EZE alone and had a similar tolerability profile
(NCT01941836).
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Thompson et al LDL-C lowering by ETC-1002 alone and with ezetimibe 557Statins are the cornerstone of prevention and treatment of Study population
cardiovascular disease but canproduce statin-associatedmuscle
symptoms in 5% to 29% of patients.1–4 There is no universally
accepted definition for statin intolerance. The National Lipid
Association Statin Intolerance Panel defines it as a patient’s
inability to tolerate$2 statins, at least 1 at the lowest approved
daily dose and another at any daily dose.1 Muscle symptoms
including pain, stiffness, cramping, or weakness, usually
without serum creatine kinase (CK) elevations, are the
primary manifestations of statin intolerance.1,4,5
Statin-associated muscle symptoms are an important
clinical problem because statin discontinuation in
hypercholesterolemic patients increases cardiovascular
risk.4 Patients who discontinue statin treatment because
of intolerance show a trend toward decreased 8-year sur-
vival compared with patients who continue statin therapy
(log-rank P value, .08).5 The challenge of muscle-related
statin intolerance and the need for research into therapies
for this population are recognized in the latest American
College of Cardiology/American Heart Association choles-
terol management guidelines,6 the National Lipid Associa-
tion’s Statin Safety Task Force recommendations,1 and the
European Atherosclerosis Society Consensus Panel state-
ment on statin-associated muscle symptoms.4
ETC-1002 is a first-in-class, once-daily, oral agent that
lowers low-density lipoprotein cholesterol (LDL-C) by
direct inhibition of hepatic adenosine triphosphate citrate
lyase, leading to reduced de novo cholesterol synthesis and
increased LDL-receptor expression.7–9 ETC-1002 in doses
from 120 mg to 240 mg daily reduced LDL-C by 27% to
43% in phase 2a clinical trials of various hypercholesterol-
emic patient populations, including patients with type 2 dia-
betes mellitus and patients with muscle-related
statin intolerance.10–12 The present phase 2b study
(NCT01941836) compared the efficacy and safety of ETC-
1002 monotherapy (120 mg or 180 mg daily) and ETC-
1002 combined with ezetimibe 10 mg (EZE) vs EZE mono-
therapy among hypercholesterolemic patients with or
without a history of statin-related muscle symptoms.Methods
Study objectives
The primary objective was to assess the LDL-C–
lowering effect of ETC-1002 monotherapy (120 mg or
180 mg daily) vs EZE monotherapy in hypercholesterol-
emic patients with or without statin intolerance. Secondary
objectives were to characterize the dose response of
ETC-1002, evaluate the impact of treatment on other lipid
and cardiometabolic biomarkers, compare the LDL-C–
lowering effect of ETC-1002 plus EZE combination
therapy with EZE monotherapy, and characterize the safety
and tolerability of the treatment regimens, including
muscle-related adverse events (AEs).Medically stable, hypercholesterolemic men and women
aged 18 through 80 years with a body mass index between
18 and 45 kg/m2 were included in the study. Eligible
patients had fasting, calculated LDL-C values between
130 and 220 mg/dL and a fasting triglyceride level
#400 mg/dL after washout of lipid-regulating drugs. The
study population included both statin-tolerant and statin-
intolerant participants. Statin intolerance was defined as
the inability to tolerate $2 statins because of muscle-
related symptoms such as pain, weakness, or cramping
that began or increased during statin therapy and resolved
on statin discontinuation. At least 1 statin must have been
administered at the lowest approved daily dose, defined
as rosuvastatin 5 mg, atorvastatin 10 mg, simvastatin
10 mg, lovastatin 20 mg, pravastatin 40 mg, fluvastatin
40 mg, or pitavastatin 2 mg. Treatment with less than the
lowest approved daily dose of a statin (ie, skipping days)
was considered equivalent to not tolerating 1 statin at the
lowest approved daily dose. Patients were excluded if
they had clinically significant cardiovascular disease
(including acute coronary syndromes, stroke, transient
ischemic attack, carotid or peripheral artery disease,
decompensated heart failure, uncontrolled hypertension,
or cardiac arrhythmias); type 1 diabetes mellitus;
uncontrolled type 2 diabetes mellitus; non–statin-related
musculoskeletal complaints; uncorrected hypothyroidism;
liver or renal dysfunction; unexplained CK elevations off
statin treatment .3 times the upper limit of normal; in-
gested ,80% of drug during single-blind run-in; or used
anticoagulants, systemic corticosteroids, cyclosporine, met-
formin, or thiazolidinediones within 3 months of screening.Overall study design and plan
This phase 2b, randomized, double-blind, active
comparator-controlled, parallel-group study was conducted
at 70 sites in the United States from September 16, 2013, to
August 7, 2014, and consisted of a 6-week screening phase
(week 26 to week 0) and a 12-week double-blind treatment
period (week 0 to week 12). Patients underwent a 5-week
washout of all lipid-regulating drugs and dietary supple-
ments and abstained from these drugs and supplements
throughout the study. Patients also underwent a 5-week,
single-blind placebo run-in during the screening period
(week 25 to week 0). This single-blind placebo run-in
period was used to eliminate patients with muscle-related
AEs during placebo treatment. Patients reporting new or
worsening unexplained muscle-related AEs during this run-
in period were excluded from the study.
Patients were stratified (1:1) by history of statin
intolerance and randomized at week 0 in a 4:4:4:1:1 ratio
to once-daily treatment with capsules containing ETC-1002
120 mg, ETC-1002 180 mg, EZE, ETC-1002 120 mg plus
EZE, or ETC-1002 180 mg plus EZE. Patients were seen at
558 Journal of Clinical Lipidology, Vol 10, No 3, June 2016weeks 26, 25, 23, 21, 0, 2, 4, 8, and 12. A contract
laboratory (Medpace Inc., Cincinnati, OH), performed all
clinical laboratory tests. LDL-C was calculated using the
Friedewald equation. Phlebotomy was performed after a
minimum 12-hour fast (water was allowed) and only if the
patient took their dose of study drug the previous day.
Individual institutional review boards approved the
clinical study protocol and informed consent documents.
Written informed consent was obtained from all partici-
pants before any study-related procedures.
Efficacy endpoints
The primary endpoint was the percent change from
baseline to week 12 in calculated LDL-C in patients treated
with ETC-1002 monotherapy vs those treated with EZE
alone. Secondary endpoints included the dose-response
relationship between ETC-1002 and the percent change in
LDL-C from baseline to week 12, the percent change in
LDL-C from baseline to week 12 in patients treated with
ETC-1002 plus EZE vs those treated with EZE alone, and
the percent change from baseline to week 12 for all
treatment groups in LDL particle number, apolipoprotein
B, total cholesterol, non–high-density lipoprotein choles-
terol (non–HDL-C), HDL-C, HDL particle number, apoli-
poprotein A-I, triglycerides, very low-density lipoprotein
(VLDL) particle number, and high-sensitivity C-reactive
protein (CRP). Lipoprotein particle number was measured
using nuclear magnetic resonance imaging.
Safety endpoints
The safety of ETC-1002 was assessed using treatment-
emergent AEs; hematology, serum chemistry, and urinaly-
sis laboratory values; physical examination findings; vital
sign measurements; electrocardiogram readings; weight;
and ankle and waist circumference measurements. AEs
were coded using the Medical Dictionary for Regulatory
Activities, version 16.0, and evaluated by the investigator
for severity and relation to study drug. Muscle-related
AEs were defined as those from the system organ class of
musculoskeletal and connective tissue disorders, except
for those that were not obviously muscle related. Terms
included in the muscle-related AE analysis were selected
from this system organ class after database lock and before
unblinding.
Statistical plan and analyses
The study was designed to include 322 patients: 92
patients in each monotherapy group and 23 patients in
each combination therapy group. Sample size calculations
were performed using nQuery Advisor, version 7.0 (Sta-
tistical Solutions, Cork, Ireland). The sample size of 92
patients per monotherapy group was expected to provide
90% power to detect a difference of 10% in the absolute
percent change from baseline to week 12 in LDL-Cbetween either ETC-1002 treatment groups and the EZE
monotherapy group. This calculation was based on a 2-
sided t test at the 5% level of significance and assumed a
common standard deviation of 15% in the statin-tolerant
patients and 22% in the statin-intolerant patients with a
dropout rate of 15%.
Efficacy analyses were performed on the modified
intent-to-treat population, which consisted of randomized
patients who had a baseline assessment, received at least
1 dose of study medication, and had at least 1 on-treatment
assessment, excluding assessments taken .2 days after a
dose of study drug. Safety analyses were performed on the
safety population, which included randomized patients who
received at least 1 dose of study drug. Baseline patient
characteristics were summarized for the safety population
by treatment group and statin-tolerance subgroup.
An analysis of covariance was used to compare each
ETC-1002 treatment group with EZE monotherapy for each
of the efficacy endpoints. The primary model included the
effects of treatment and statin intolerance and the baseline
value as a covariate. Baseline was defined as the mean of
values from weeks21 and 0 for LDL-C, non–HDL-C, total
cholesterol, HDL-C, and triglycerides. For all other lipid
and biomarker measures, baseline was defined as the last
value before the first dose of study drug. Missing values at
week 12 were imputed using the last-observation carried-
forward procedure. When LDL-C could not be calculated
(ie, triglycerides .400 mg/dL), beta-quantification
measurements were used to determine LDL-C values.
Least-square (LS) means and standard errors were obtained
for each treatment group; differences in LS means and
P values were obtained for the treatment comparisons.
Graphical methods (eg, normal probability plot and histo-
gram of residuals, plot of residuals vs predicted values)
or analytical methods (eg, Shapiro–Wilk test), or both,
were used to assess the model assumptions. Because of
departures from normality observed in the parameters of
triglycerides, CRP, and VLDL particle number, nonpara-
metric analyses were performed for these measures, with
P values obtained from the Wilcoxon rank-sum test and
median values presented.
Actual values, changes from baseline, and percent
changes from baseline in calculated LDL-C and secondary
lipid and biomarker measures were summarized using
descriptive statistics by treatment group and time point.
Percent changes from baseline in LDL-C also were sum-
marized by statin-tolerance subgroup. To assess the dose-
response relationship for ETC-1002 monotherapy, the
primary analysis of covariance model was used for the
comparison of ETC-1002 120 mg and ETC-1002 180 mg.
Statistical testing of the efficacy endpoints was 2-sided and
conducted at the 5% level of significance with no adjust-
ment for multiple comparisons.
For the evaluation of safety, the incidence of AEs was
summarized by system organ class and preferred term for
each treatment group. Muscle-related AEs also were sum-
marized by statin-tolerance subgroup. Actual values and
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vital sign measurements, electrocardiogram tracings, body
weight, and ankle and waist circumference measurements
were summarized using descriptive statistics by treatment
group and time point.Results
Patient disposition and baseline characteristics
Of 690 patients screened, 341 were excluded, mainly for
failure to satisfy inclusion criteria (Fig. 1). Of the 349 random-
ized patients (177 statin intolerant and 172 statin tolerant), 309
patients completed the study. The 40 who discontinued partic-
ipation did so most commonly because of AEs. A higher per-
centage of statin-tolerant patients (93%) than statin-intolerant
patients (84%) completed the study. The safety population
included 348 patients as 1 statin-tolerant patient
discontinued before receiving any study drug.
Most patients were non-Hispanic Caucasians with
similar numbers of men and women (Table 1). Mean age,
baseline lipid values, and National Cholesterol Education
Program Adult Treatment Panel (NCEP ATP) III risk cate-
gory were slightly higher in statin-intolerant patients. The
most common prestudy statin-associated muscle com-
plaints were bilateral calf and thigh pain (data not shown).
Most statin-intolerant patients historically experienced the
onset of statin-associated muscle symptoms within 1 to
2 weeks of statin initiation and most had resolution of
symptoms within 1 to 2 weeks of discontinuation.Figure 1 Disposition of patients. *One patient who was statin tolera
EZE, ezetimibe; mITT, modified intent-to-treat; Pop., population.Efficacy endpoints
ETC-1002 alone or in combination with EZE reduced
LDL-C from baseline to week 12 more than EZE mono-
therapy (Table 2). LDL-C reductions were greatest with the
combination of ETC-1002 120 mg (43%) or 180 mg (48%)
plus EZE (P, .0001 vs EZE alone, both comparisons). The
combination treatment effect of ETC-1002 plus EZE was
approximately equal to the sum of their individual effects
on LDL-C. The LDL-C reduction was slightly, but not
significantly, higher with ETC-1002 180 mg alone (30%)
than with 120 mg alone (27%) (P 5 .15). The percent
reductions in LDL-C with ETC-1002 were similar in
statin-intolerant and statin-tolerant patients (Fig. 2).
LDL-C reductions were apparent and steady after 2 weeks
of treatment (Fig. 3).
ETC-1002 alone or with EZE reduced LDL particle
number, apolipoprotein B, total cholesterol, and non–HDL-
C more than EZE alone (Table 2). Median values for CRP
decreased from baseline to the week 12 endpoint by 30%
with ETC-1002 120 mg and 40% with ETC-1002
180 mg. These CRP reductions in the ETC-1002 monother-
apy groups were significantly greater (P , .01, both
comparisons) than the 10% reduction observed with EZE
alone (Table 2). ETC-1002 had minimal effect on triglycer-
ides and VLDL particle number (Table 2). HDL-C
decreased with ETC-1002 treatment (by 3% to 6%) and
increased with EZE alone (by 5%; P , .0001 to P , .05
for ETC-1002 groups vs EZE alone; Table 2). ETC-1002
did not alter HDL particle number or apolipoprotein A-I
vs EZE alone, although apolipoprotein A-I did decreasent was randomized but discontinued before receiving study drug.
Table 1 Baseline demographic and clinical characteristics
Characteristics
Safety population
Statin intolerant,
n 5 177
Statin tolerant,
n 5 171
ETC-1002 120 mg,
n 5 99
ETC-1002 180 mg,
n 5 100
EZE 10 mg,
n 5 99
ETC-1002, 120 mg 1
EZE 10 mg,
n 5 26
ETC-1002 180 mg 1
EZE 10 mg
n 5 24
Demographic
Age, y 62 6 9 57 6 9 61 6 10 59 6 9 60 6 10 59 6 10 59 6 9
Women, % 57 47 54 51 52 54 54
Caucasian, % 89 91 91 91 88 92 92
Not Hispanic/Latino, % 94 84 92 85 90 92 92
NCEP ATP III risk category
very high, %
14 3 11 7 8 8 8
NCEP ATP III risk category
high, %
14 9 14 10 11 12 8
NCEP ATP III risk category
moderate, %
41 50 38 49 49 42 46
NCEP ATP III risk category
low, %
32 38 36 34 32 39 38
Clinical
LDL-C, mg/dL 169 6 25 160 6 25 164 6 28 166 6 24 165 6 25 162 6 26 162 6 27
Total cholesterol, mg/dL 255 6 33 244 6 31 249 6 31 253 6 33 248 6 32 247 6 35 246 6 32
HDL-C, mg/dL 53 6 13 51 6 15 54 6 16 52 6 13 49 6 12 51 6 15 52 6 16
Triglycerides, mg/dL* 157 (52–365) 150 (38–434) 136 (71–375) 162 (38–371) 163 (64–434) 161 (81–332) 151 (50–343)
CRP, mg/L*,† 1.90 (0.2–31.7) 2.20 (0.1–22.5) 1.60 (0.2–19.2) 2.50 (0.1–20.3) 2.60 (0.3–31.7) 1.85 (0.2–19.5) 1.25 (0.2–4.7)
SBP, mm Hg 124 6 11 126 6 12 126 6 11 125 6 12 126 6 12 126 6 11 119 6 12
DBP, mm Hg 77 6 8 78 6 8 77 6 8 78 6 7 78 6 7 77 6 7 76 6 9
Weight, kg 86 6 17 88 6 19 87 6 18 89 6 19 85 6 17 88 6 20 83 6 22
BMI, kg/m2 30 6 5 30 6 5 31 6 6 31 6 5 30 6 5 30 6 5 28 6 5
BMI, body mass index; DBP, diastolic blood pressure; EZE, ezetimibe; HDL-C, high-density lipoprotein cholesterol; CRP, high-sensitivity C-reactive protein; LDL-C, low-density lipoprotein cholesterol; NCEP
ATP III, National Cholesterol Education Program Adult Treatment Panel III; SBP, systolic blood pressure.
Values are mean 6 SD. Baseline defined as the mean of the values from weeks 21 and 0, unless otherwise indicated.
*Median values (minimum, maximum).
†Baseline defined as the last value before the first dose of study drug.
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Table 2 Percent changes from baseline to week 12 in lipids and CRP
Endpoint
mITT population
ETC-1002 120 mg,
n 5 97
ETC-1002 180 mg,
n 5 99
EZE 10 mg,
n 5 98
ETC-1002 120 mg 1
EZE 10 mg,
n 5 24
ETC-1002 180 mg 1
EZE 10 mg, n 5 22
Primary
LDL-C, mg/dL 227.5 6 1.3b 230.1 6 1.3a 221.2 6 1.3 243.1 6 2.6a 247.7 6 2.8a
Secondary
LDL particle number, nmol/L 221.8 6 1.7b 224.6 6 1.8a 212.7 6 1.7 235.0 6 3.7a 237.0 6 3.6a
Apolipoprotein B, mg/dL 219.3 6 1.3‡ 221.3 6 1.3† 215.2 6 1.2 232.7 6 2.7a 235.2 6 2.6a
Total cholesterol, mg/dL 219.3 6 0.9b 220.7 6 0.9a 214.3 6 0.9 230.6 6 1.9a 234.3 6 2.0a
Non–HDL-C, mg/dL 223.2 6 1.2b 225.3 6 1.1a 218.7 6 1.2 237.4 6 2.3a 242.4 6 2.4a
HDL-C, mg/dL 25.8 6 1.4a 24.8 6 1.4a 5.0 6 1.4 23.1 6 2.8c 23.7 6 3.0b
HDL particle number, mmol/L 5.0 6 1.3 6.2 6 1.4 6.7 6 1.3 7.3 6 2.9 5.1 6 2.8
Apolipoprotein A-I, mg/dL 20.2 6 1.1 0.1 6 1.2 2.0 6 1.1 22.8 6 2.4 24.1 6 2.4c
Triglycerides, mg/dL*,† 0.0 (41.6) 22.7 (46.2) 27.0 (34.9) 218.9 (25.5) 212.2 (36.5)
VLDL particle number, nmol/L* 22.7 (68.5) 15.3 (80.5) 212.6 (63.4) 211.7 (80.1) 12.0 (78.1)
CRP, mg/L*,†,‡ 230.1 (55.4)b 240.2 (53.3)b 210.5 (59.0) 238.1 (83.2) 225.6 (37.2)c
CRP, high-sensitivity C-reactive protein; EZE, ezetimibe; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; mITT, modified intent-to-treat; VLDL, very low-density
lipoprotein.
Values are least-squares mean 6 SE, unless otherwise indicated.
Baseline defined as the mean of the values from weeks 21 and 0 unless otherwise indicated. Week 12 endpoint is the week 12 value or last observation carried forward.
aP , .0001.
bP # .01.
cP # .05 vs EZE alone using an analysis of covariance model with terms for treatment and statin intolerance and baseline value as a covariate, unless otherwise indicated.
*Median (interquartile range) values.
†Non-parametric analysis vs EZE using Wilcoxon rank-sum test.
‡Baseline defined as the last value before the first dose of study drug.
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Figure 2 Percent changes from baseline in LDL-C, stratified by statin tolerance. Week 12 or last observation carried forward is the end-
of-study endpoint and differs slightly from week 12 value; P values vs EZE monotherapy were determined by an analysis of covariance
model with terms for treatment and statin intolerance and baseline value as a covariate. *P # .05 vs EZE; †P # .01 vs EZE; ‡P , .0001 vs
EZE. EZE, ezetimibe; LS, least square. Error bars represent standard error.
Figure 3 Percent changes from baseline in LDL-C by treatment
group and time. P values vs EZE at week 12 endpoint are shown.
Week 12 or last observation carried forward is the end-of-study
endpoint and differs slightly from week 12 value; P values vs
EZE monotherapy were determined by an analysis of covariance
model with terms for treatment and statin intolerance and baseline
value as a covariate. EZE, ezetimibe; LS, least square.
562 Journal of Clinical Lipidology, Vol 10, No 3, June 2016more with ETC-1002 180 mg plus EZE than with
EZE alone.
Safety endpoints
The incidence of AEs in each ETC-1002 monotherapy
group was similar to EZE alone (Table 3). Most AEs were
mild or moderate in severity. AEs deemed possibly, prob-
ably, or definitely related to study drug were least common
with ETC-1002 120 mg and most frequent with ETC-1002
180 mg plus EZE. The frequency of AEs resulting in study
discontinuation was similar between the ETC-1002 treat-
ment groups and EZE. More statin-intolerant patients
(n 5 17) experienced AEs resulting in discontinuation
than did statin-tolerant patients (n 5 3). Four serious AEs
were reported (Table 3), 3 of which were unrelated to study
drug and did not result in discontinuation (hemothorax with
ETC-1002 120 mg, pancreatitis relapse with ETC-1002
180 mg, and transient ischemic attack with EZE). One sud-
den death of unknown cause in a patient taking ETC-1002
120 mg was deemed possibly related to study drug as a
temporal relationship could not be excluded.
Muscle AEs were less frequent and caused fewer
discontinuations with ETC-1002 monotherapy than with
EZE. In the entire study population, myalgia was the most
common muscle-related AE, occurring in 3% of patients
treated with ETC-1002 120 mg, 1% with ETC-1002
180 mg, 6% with EZE alone, 8% with ETC-1002 120 mg
plus EZE, and 4% with ETC-1002 180 mg plus EZE.
Muscle-related AEs were more common among statin-
intolerant than statin-tolerant patients (Table 4). The most
common muscle-related AE in statin-intolerant patientswas myalgia, which was least frequent in the ETC-1002
monotherapy groups.
Overall, no clinically meaningful, dose-related trends in
laboratory changes or abnormalities were observed. There
also were no clinically meaningful changes in physical
examination findings, vital sign measurements, electrocar-
diogram readings, weight, or waist or ankle circumference
measurements. Alanine aminotransferase or aspartate
aminotransferase, or both, increased .3 times the upper
limit of normal at any measurement in 1 patient treated
with ETC-1002 120 mg, 2 patients with ETC-1002 180 mg,
1 patient with EZE, and 1 patient with ETC-1002 120 mg
Table 3 Safety overview: treatment-emergent adverse events
Adverse events
Safety population
ETC-1002 120 mg,
n 5 99
ETC-1002 180 mg,
n 5 100 EZE 10 mg, n 5 99
ETC-1002 120 mg 1
EZE 10 mg, n 5 26
ETC-1002 180 mg 1
EZE 10 mg, n 5 24
Overview
Any AE(s) 50 (51) 55 (55) 53 (54) 14 (54) 17 (71)
Serious AE(s)* 2 (2) 1 (1) 1 (1) 0 0
Study drug-related
AEs†
13 (13) 18 (18) 19 (19) 5 (19) 10 (42)
Discontinuation due
to AEs
3 (3) 6 (6) 8 (8) 2 (8) 1 (4)
Most common‡
Constipation 3 (3) 1 (1) 1 (1) 0 2 (8)
Nasopharyngitis 3 (3) 5 (5) 4 (4) 0 2 (8)
Upper respiratory
tract infection
6 (6) 6 (6) 1 (1) 1 (4) 0
Urinary tract
infection
0 4 (4) 6 (6) 0 1 (4)
ALT increased 0 0 1 (1) 2 (8) 0
AST increased 0 0 0 2 (8) 0
Blood CK increased 1 (1) 4 (4) 1 (1) 2 (8) 0
Arthralgia 4 (4) 1 (1) 4 (4) 2 (8) 1 (4)
Back pain 1 (1) 1 (1) 8 (8) 0 0
Myalgia 3 (3) 1 (1) 6 (6) 2 (8) 1 (4)
Headache 3 (3) 2 (2) 1 (1) 4 (15) 0
AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CK, creatine kinase; EZE, ezetimibe.
Values are n (%).
*Serious AEs included 1 patient with hemothorax and 1 patient with sudden death (ETC-1002,120 mg), pancreatitis relapse (ETC-1002 180 mg), and transient ischemic attack (EZE).
†AEs were categorized as drug related if relationship to study drug was deemed possible, probable, or definite, or if relationship to study drug was not recorded. The most common drug-related AEs were
muscle spasms (3%), peripheral edema (2%), myalgia (2%), and muscle weakness (2%) with ETC-1002 120 mg; upper respiratory tract infection (2%), abnormal liver function test (2%), and pruritus (2%) with
ETC-1002 180 mg; myalgia (6%), arthralgia (4%), and muscle spasms (3%) with EZE; and increased ALT (8%), increased AST (8%), and myalgia (8%) in the ETC-1002 120 mg plus EZE combination group. No
drug-related AE was experienced by .1 patient treated with ETC-1002 180 mg plus EZE.
‡Most common AEs were those occurring in $5% patients/group.
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Table 4 Safety overview: muscle-related treatment-emergent adverse events
Muscle-related AEs by subgroup
Safety population
ETC-1002 120 mg ETC-1002 180 mg EZE 10 mg ETC-1002 120 mg + EZE 10 mg ETC-1002 180 mg + EZE 10 mg
Statin-intolerant patients (n 5 51) (n 5 51) (n 5 51) (n 5 12) (n 5 12)
Overview of muscle-related AEs
Any muscle-related AE 7 (14) 6 (12) 9 (18) 2 (17) 2 (17)
Leading to discontinuation 1 (2) 2 (4) 5 (10) 0 0
Muscle-related AEs by MedDRA preferred term*
Muscle spasms 3 (6) 2 (4) 1 (2) 0 0
Muscular weakness 2 (4) 1 (2) 1 (2) 0 0
Musculoskeletal chest pain 0 1 (2) 0 0 0
Musculoskeletal stiffness 0 0 1 (2) 0 0
Myalgia 2 (4) 1 (2) 6 (12) 2 (17) 1 (8)
Pain in extremity 1 (2) 1 (2) 3 (6) 0 1 (8)
Sensation of heaviness 0 0 1 (2) 0 0
Statin-tolerant patients n 5 48 n 5 49 n 5 48 n 5 14 n 5 12
Overview of muscle-related AEs
Any muscle-related AE 1 (2) 0 3 (6) 0 1 (8)
Leading to discontinuation 0 0 1 (2) 0 0
Muscle-related AEs by MedDRA preferred term*
Muscle spasms 0 0 2 (4) 0 1 (8)
Musculoskeletal pain 0 0 1 (2) 0 0
Myalgia 1 (2) 0 0 0 0
AE, adverse event; EZE, ezetimibe; MedDRA, Medical Dictionary for Regulatory Activities, version 16.0.
Values are n (%).
*Prespecified analysis of all musculoskeletal and connective tissue disorders AE terms except arthralgia, back pain, bone pain, bunion, bursitis, groin pain, intervertebral degeneration, intervertebral disc
protrusion, joint stiffness, joint swelling, neck pain, osteoarthritis, plantar fasciitis, rotator cuff syndrome, and synovial cyst.
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EZE experienced a CK level .10 times the upper limit of
normal, which occurred after heavy physical exertion and
was accompanied by myalgia.Discussion
In this phase 2b study, ETC-1002 alone reduced LDL-C
up to 30%, which was significantly greater than the
reduction achieved with EZE monotherapy. The greatest
mean reductions in LDL-C, which reached 43% and 48%,
occurred with the combination of ETC-1002 120 mg or
180 mg with EZE, respectively. The decreases in LDL-C
with ETC-1002, EZE, and the combination occurred within
2 weeks of treatment and were maintained throughout the
study. LDL-C reductions in statin-intolerant patients
appeared similar to those in statin-tolerant patients. This
finding is noteworthy considering that statin-intolerant
patients had a higher baseline risk for cardiovascular
disease than did statin-tolerant patients, with 28% vs 12%
classified as ‘‘high’’ or ‘‘very high’’ risk per NCEP ATP III
criteria, respectively.
ETC-1002 alone or with EZE also reduced secondary
lipid endpoints including non–HDL-C, total cholesterol,
apolipoprotein B, and LDL particle number significantly
more than EZE alone. CRP decreased more with ETC-1002
alone and ETC-1002 180 mg plus EZE than with EZE
alone. There were no significant differences between ETC-
1002 and EZE for triglycerides, HDL particle number, and
VLDL particle number, but ETC-1002 did reduce HDL-C
slightly.
ETC-1002 120 mg and ETC-1002 180 mg were well
tolerated both alone and combined with EZE 10 mg daily,
and safety profiles were similar across all treatment groups.
Frequencies of muscle-related AEs were low in all
treatment groups and more common in patients with a
history of statin intolerance. The greater LDL-C–lowering
effect of ETC-1002 vs EZE did not produce more muscle-
related AEs. Rather, rates of muscle-related AEs were
slightly lower with ETC-1002 monotherapy than with EZE
alone.
This is the first clinical study to assess ETC-1002
combined with EZE, the agent most commonly prescribed
for patients with statin intolerance.5 The incremental
LDL-C reduction with combination therapy is likely due
to the complementary mechanisms of action of the 2 drugs:
inhibition of hepatic cholesterol synthesis with ETC-
10027,8 and inhibition of intestinal cholesterol absorption
with EZE.13 The 43% to 48% reduction in LDL-C with
ETC-1002 120 mg or 180 mg plus EZE is comparable to
the 42% to 56% LDL-C reduction observed when EZE is
combined with moderate-dose statins13 and to the $50%
reduction with high-intensity statin monotherapy.6
The results from this study are consistent with findings
from earlier studies comparing ETC-1002 with placebo.
ETC-1002 in doses up to 120 mg daily reduced LDL-C by27% in patients with hypercholesterolemia treated for
12 weeks10 and by 43% in diabetic patients with hypercho-
lesterolemia treated for 4 weeks.11 ETC-1002 was well
tolerated in these trials, with an AE profile similar to pla-
cebo.10,11 In a trial of 56 hypercholesterolemic patients
with a history of statin-associated muscle complaints
treated for 8 weeks, ETC-1002 in doses up to 240 mg daily
reduced LDL-C by 32% from baseline (P , .0001
compared with placebo).12 Muscle-related AEs occurred
with similar frequency with ETC-1002 and placebo and
caused no discontinuations in the ETC-1002–treated
patients.12 Reductions in CRP achieved with ETC-1002
monotherapy in the present study (up to 40%) also were
observed in previous studies (41% to 42%).11,12
Patients with a history of statin-associated muscle
symptoms are difficult to treat. Current recommendations
for the management of patients with statin-associated muscle
symptoms include the use of maximally tolerated statins
combined with nonstatin lipid-lowering therapies as
needed.4,14 EZE has been shown to reduce LDL-C by 16%
to 17% in statin-intolerant patients15,16 and is recommended
for statin-intolerant patients, as are bile acid sequestrants,
which may be poorly tolerated and fenofibrate.4,14 Coleseve-
lam17 and fenofibrate18 can reduce LDL-C by approximately
20% in hypercholesterolemic patients but have not to our
knowledge been studied in patients with statin-associated
muscle symptoms. The investigational proprotein convertase
subtilisin/kexin type 9 inhibitors may offer a future therapeu-
tic alternative for patients with statin-associated muscle
complaints.4 Evolocumab lowered LDL-C up to 56% after
12 weeks of treatment in statin-intolerant patients,19 and alir-
ocumab lowered LDL-C by 45% after 24 weeks of treatment
in statin-intolerant patients.20
There are limitations to the present study. The overall
sample size was relatively small, and the combination
treatment group was 25% the size of the monotherapy
groups. This design was used because the primary goal was
to compare LDL-C effects between ETC-1002 (120 mg or
180 mg) and EZE monotherapy. The study did not include a
placebo group but used EZE as an active comparator
because it is commonly prescribed to statin-intolerant
patients. Baseline triglyceride and CRP levels differed
among the treatment groups, and the effect of these
differences is unknown. Some study participants were
statin tolerant, but this diagnosis was not tested with a
statin-treatment arm.
Conclusion
There is a need for alternative oral treatment strategies
for hypercholesterolemic patients who cannot sufficiently
reduce their LDL-C with available agents, including
patients with intolerance to statins.1,21 The results of this
study suggest that ETC-1002 with or without EZE may
be a useful treatment in patients with hypercholesterolemia,
including those who are unable to tolerate statins because
of muscle side effects.
566 Journal of Clinical Lipidology, Vol 10, No 3, June 2016Acknowledgment
The authors thank all investigators, their staffs, and all
patient volunteers. We also thank Medpace Inc.,
of Cincinnati, OH, for their oversight of patient randomi-
zation, clinical laboratory services, statistical analyses,
clinical monitoring, data management, clinical program-
ming, and medical writing.
The authors thank Darlene J. Benson, RPh, ELS, and
Lamara D. Shrode, PhD, CMPP, of The JB Ashtin Group,
Inc., for assistance in preparing this article for publication
based on the authors’ input and direction.Financial disclosure
The design, study conduct, analysis, and financial
support of this clinical trial were provided by Esperion
Therapeutics, Inc. Esperion participated in the interpreta-
tion of data, review, and approval of the publication. All
authors contributed to the development of the content;
reviewed and approved the article; and maintained control
over the final content. Dr Thompson has received research
support from Genomas, Sanofi, Regeneron, Esperion,
Amarin, and Pfizer. He has served as a consultant for
Amgen, Regeneron, Merck, Genomas, Sanofi, Esperion,
and Amarin and has received speaker honoraria from
Merck, AstraZeneca, Amgen, and Regeneron. In addition,
he owns stock in AbbVie Inc., Abbott Labs, General
Electric, and Johnson & Johnson. He has also provided
expert legal testimony on exercise-related cardiac events
and statin myopathy. Dr Orloff has no relationship with
industry to declare. Dr McKenney is an employee of
National Clinical Research, which has received funding
for lipid-modifying research from Sanofi, Regeneron,
Esperion Therapeutics, Merck, Amgen, Pfizer, and Lilly
and consulting fees from Merck. Dr Ballantyne has
received grant and/or research support from Abbott
Diagnostic, Amarin, Amgen, Eli Lilly, Esperion Thera-
peutics, Novartis, Pfizer, Otsuka, Regeneron, Roche
Diagnostic, Sanofi-Synthelabo, Takeda, NIH, AHA, and
ADA. He has served as a consultant for Abbott Di-
agnostics, Amarin, Amgen, AstraZeneca, Eli Lilly, Espe-
rion, Genzyme, Matinas BioPharma Inc, Merck, Novartis,
Pfizer, Regeneron, Roche, and Sanofi-Synthelabo. Mr
Hanselman, Ms MacDougall, Ms Margulies, and Dr
Newton are full-time employees of Esperion Therapeutics,
Inc.
References
1. Guyton JR, Bays HE, Grundy SM, Jacobson TA. An assessment by the
Statin Intolerance Panel: 2014 update. J Clin Lipidol. 2014;8(Suppl 3):
S72–S81.
2. Ito MK, Maki KC, Brinton EA, et al. Muscle symptoms in statin users,
associations with cytochrome P450, and membrane transporter inhib-
itor use: a subanalysis of the USAGE study. J Clin Lipid. 2014;8:
69–76.3. Parker BA, Capizzi JA, Grimaldi AS, et al. Effect of statins on skeletal
muscle function. Circulation. 2013;127:96–103.
4. Stroes ES, Thompson PD, Corsini A, et al. European Atherosclerosis
Society Consensus Panel. Statin-associated muscle symptoms: impact
on statin therapy-European Atherosclerosis Society Consensus Panel
Statement on Assessment, Aetiology and Management. Eur Heart J.
2015;36:1012–1022.
5. Mampuya WM, Frid D, Rocco M, et al. Treatment strategies in
patients with statin intolerance: the Cleveland Clinic experience. Am
Heart J. 2013;166:597–603.
6. Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA
guideline on the treatment of blood cholesterol to reduce athero-
sclerotic cardiovascular risk in adults: a report of the American
College of Cardiology/American Heart Association Task Force
on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):
2889–2934.
7. Pinkosky SL, Filippov S, Srivastava RA, et al. AMP-activated protein
kinase and ATP-citrate lyase are two distinct molecular targets for
ETC-1002, a novel small molecule regulator of lipid and carbohydrate
metabolism. J Lipid Res. 2013;54:134–151.
8. Filippov S, Pinkosky SL, Newton RS. LDL-cholesterol reduction in
patients with hypercholesterolemia by modulation of adenosine
triphosphate-citrate lyase and adenosine monophosphate-activated
protein kinase. Curr Opin Lipidol. 2014;25:309–315.
9. Berkhout TA, Havekes LM, Pearce NJ, Groot PH. The effect of
(-)-hydroxycitrate on the activity of the low-density-lipoprotein
receptor and 3-hydroxy-3-methylglutaryl-CoA reductase levels in
the human hepatoma cell line Hep G2. Biochem J. 1990;272:
181–186.
10. Ballantyne CM, Davidson MH, MacDougall DE, et al. Efficacy and
safety of a novel dual modulator of adenosine triphosphate-citrate
lyase and adenosine monophosphate-activated protein kinase in
patients with hypercholesterolemia: results of a multicenter, random-
ized, double-blind, placebo-controlled, parallel-group trial. J Am
Coll Cardiol. 2013;62:1154–1162.
11. Gutierrez MJ, Rosenberg NL, MacDougall DE, et al. Efficacy and
safety of ETC-1002, a novel investigational low-density lipoprotein-
cholesterol-lowering therapy for the treatment of patients with hyper-
cholesterolemia and type 2 diabetes mellitus. Arterioscler Thromb
Vasc Biol. 2014;34:676–683.
12. Thompson PD, Rubino J, Janik MJ, et al. Use of ETC-1002 to treat
hypercholesterolemia in patients with statin intolerance. J Clin Lipi-
dol. 2015;9:295–304.
13. Ezetimibe (Zetia) [package insert]. Whitehouse Station, NJ: Merck &
Co., Inc.; 2013.
14. Rosenson RS, Baker SK, Jacobson TA, Kopecky SL, Parker BA. An
assessment by the Statin Muscle Safety Task Force: 2014 update.
J Clin Lipidol. 2014;8(Suppl 3):S58–S71.
15. Stein EA, Ballantyne CM, Windler E, et al. Efficacy and tolerability of
fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of
fluvastatin XL 80 mg with ezetimibe in patients with a history of
muscle-related side effects with other statins. Am J Cardiol. 2008;
101:490–496.
16. Saougos VG, Tambaki AP, Kalogirou M, et al. Differential effect of
hypolipidemic drugs on lipoprotein-associated phospholipase A2.
Arterioscler Thromb Vasc Biol. 2007;27:2236–2243.
17. Davidson MH, Dillon MA, Gordon B, et al. Colesevelam hydrochlo-
ride (cholestagel): a new, potent bile acid sequestrant associated
with a low incidence of gastrointestinal side effects. Arch Intern
Med. 1999;159:1893–1900.
18. Knopp RH, Brown WV, Dujovne CA, et al. Effects of fenofibrate on
plasma lipoproteins in hypercholesterolemia and combined hyperlipid-
emia. Am J Med. 1987;83:50–59.
19. Stroes E, Colquhoun D, Sullivan D, et al, GAUSS-2 Investigators.
Anti-PCSK9 antibody effectively lowers cholesterol in patients with
statin intolerance: the GAUSS-2 randomized, placebo-controlled
phase 3 clinical trial of evolocumab. J Am Coll Cardiol. 2014;63:
2541–2548.
Thompson et al LDL-C lowering by ETC-1002 alone and with ezetimibe 56720. Moriarty PM, Thompson PD, Cannon CP, et al. ODYSSEY ALTER-
NATIVE: efficacy and safety of the proprotein convertase subtilisin/-
kexin type 9 monoclonal antibody, alirocumab, versus ezetimibe, in
patients with statin intolerance as defined by a placebo run-in andstatin rechallenge arm. Presented at: American Heart Association
2014 Scientific Sessions; November 17, 2014; Chicago, IL.
21. Kane JP. New horizons in lipid management. J Am Coll Cardiol. 2013;
62:1163–1164.
